Facet Board Recommends Rejection Of Biogen Bid
Facet Biotech's board of directors recommends rejection of $493 million Biogen takeover offer
10:31AM 12/10/09
Biogen Raises Facet Offer To $17.50 Per Share
Biogen Idec says it is raising unsolicited offer for Facet Biotech offer to $493M from $356M
05:25PM 12/03/09
Acting on Positive Momentum (Deep in the Money Calls $)
With the tech sector on the upswing, this big-name software company is due for its next move higher.
09:33AM 12/02/09
Research Firm Lays Out Surprise Bio Events for 2010: BioBuzz
Stocks will move if any of these unexpected events come true.
11:16AM 11/30/09
Taking Flight With a New Name (Deep in the Money Calls $)
After more than two months of edging lower, this airline stock appears ready to rally.
10:19AM 11/27/09
Plugging In to a New Play (Deep in the Money Calls $)
This dividend-rich utility is trading at some of the lowest multiples in its sector.
10:11AM 11/25/09
Fitz Bits: Wait for a Retest in Ford (RealMoney.com $)
I'd be a buyer if the stock holds up at $8.
11:00AM 11/23/09
Going Shopping (Deep in the Money Calls $)
This high-quality retail name has experienced a nice pullback and is more likely to bounce than fall further.
09:35AM 11/20/09
Genentech, Biogen Get FDA Request On Rituxan
Genentech, Biogen Idec get FDA request on application for Rituxan's use in leukemia
04:48PM 11/18/09
All That Glitters Is Not Gold (Deep in the Money Calls $)
Sometimes it's silver, as this strong performer in the precious-metals sector illustrates.
10:04AM 11/18/09
Genzyme's Termeer: Worst Biotech CEO of '09
Genzyme CEO Henri Termeer is Adam Feuerstein's Worst Biotech CEO of the Year for 2009.
12:31PM 11/17/09
Practicing Balance With P&G: China Watch
By Brittany Umar | By Stephanie Link
NEW YORK -- Stephanie Link, director of research for Action Alerts PLUS, explains why she is still such a fan of Procter & Gamble and why this stock could be a perfect balance for your China portfolio.
05:00AM 11/09/09
Betting on an Industrial Juggernaut (Deep in the Money Calls $)
This company is benefiting from excellent management and a good mix of products that will do well in this economy. Also, updating prior stock picks.
09:38AM 11/06/09
Alnylam Takes Wider Loss On Administrative Costs
Alnylam says 3Q loss deepened as revenue edged lower and administrative spending increased
05:13PM 11/04/09
Human Genome Calls Second Lupus Drug Study a Success
Benlysta did not perform as well as in first pivotal study.
05:52AM 11/02/09



Connect with TheStreet